Kentaro Yoshimatsu
Gründer bei Rin Institute, Inc.
Aktive Positionen von Kentaro Yoshimatsu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | - | - |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Direktor/Vorstandsmitglied | 21.01.2016 | - |
Gründer | 21.01.2016 | - | |
Präsident | 21.01.2016 | - |
Karriereverlauf von Kentaro Yoshimatsu
Ehemalige bekannte Positionen von Kentaro Yoshimatsu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EISAI CO., LTD. | Technik-/Wissenschafts-/F&E-Leiter | 07.01.2010 | 30.09.2011 |
Corporate Officer/Principal | 07.01.2010 | 16.09.2010 | |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Präsident | 06.07.2011 | - |
Ausbildung von Kentaro Yoshimatsu
University of Tokyo | Doctorate Degree |
Statistik
International
Japan | 5 |
Vereinigte Staaten | 2 |
Operativ
President | 2 |
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EISAI CO., LTD. | Health Technology |
Private Unternehmen | 3 |
---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Health Technology |
- Börse
- Insiders
- Kentaro Yoshimatsu
- Erfahrung